 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
Mycoplasma pneumoniae macrolide resistance during 2015-2016 at a secondary emergency hospital in Fuji city |
| Language |
J |
| AuthorList |
Yoshiki Kusama1,3), Manabu Koshiba2), Katsunori Sano2) |
| Affiliation |
1) Department of Pediatrics, Fuji City General Hospital
2) Department of Clinical Laboratory, Numazu City Hospital
3) Department of Pediatrics, The Jikei University School of Medicine |
| Publication |
J.J.C.M.: 26 (3), 244-247, 2016 |
| Received |
February 12, 2016 |
| Accepted |
April 4, 2016 |
| Abstract |
In this study, we analyzed mutations in 23S rRNA, a gene related to macrolide resistance in Mycoplasma pneumoniae, using 32 throat swabs of pediatric patients at a secondary emergency hospital in Fuji city. 23S rRNA was detected in 30 samples via polymerase chain reaction. The 23S rRNA mutation (2063 or 2064 mutant) was detected in 23 throat swabs, comprising 76.7% of the tested samples. Among 23 cases where macrolides (clarithromycin and azithromycin) were used as the initial treatment, the frequency of alteration in the antibiotic used was 0% in the group without the gene mutation and 52.6% in the gene-mutated group. Among 11 patients treated with macrolides only, the median duration between initial administration and defervescence was 2 days in patients without the gene mutation and 4 days in patients with the gene mutation. Given that approximately half of the patients with the gene mutation could be treated with macrolides alone, and because the median duration between the administration of tosufloxacin and defervescence was 6.5 days, we suggest that macrolides should be the initial drug used for treatment of Mycoplasma pneumoniae infection, regardless of the presence of the 23S rRNA mutation. |
| Keywords |
Mycoplasma pneumoniae |
|
